Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Moodys
McKinsey
Mallinckrodt
Dow

Last Updated: January 25, 2020

DrugPatentWatch Database Preview

Bionpharma Inc Company Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the competitive landscape for BIONPHARMA INC, and what generic alternatives to BIONPHARMA INC drugs are available?

BIONPHARMA INC has thirty-seven approved drugs.

There are four US patents protecting BIONPHARMA INC drugs.

There are ten patent family members on BIONPHARMA INC drugs in thirteen countries and forty-one supplementary protection certificates in twelve countries.

Summary for Bionpharma Inc
International Patents:10
US Patents:4
Tradenames:35
Ingredients:31
NDAs:37
Drug Master File Entries: 2
Patent Litigation for Bionpharma Inc: See patent lawsuits for Bionpharma Inc

Drugs and US Patents for Bionpharma Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bionpharma Inc PARICALCITOL paricalcitol CAPSULE;ORAL 202539-002 Mar 27, 2014 AB RX No No   Start Trial   Start Trial
Bionpharma Inc BENZONATATE benzonatate CAPSULE;ORAL 081297-001 Jan 29, 1993 AA RX No No   Start Trial   Start Trial
Bionpharma Inc CETIRIZINE HYDROCHLORIDE ALLERGY cetirizine hydrochloride CAPSULE;ORAL 022429-004 Jul 23, 2009 OTC Yes Yes   Start Trial   Start Trial
Bionpharma Inc ETHOSUXIMIDE ethosuximide CAPSULE;ORAL 040430-001 Oct 28, 2002 AB RX No No   Start Trial   Start Trial
Bionpharma Inc STAVZOR valproic acid CAPSULE, DELAYED RELEASE;ORAL 022152-001 Jul 29, 2008 DISCN Yes No   Start Trial   Start Trial
Bionpharma Inc LOPERAMIDE HYDROCHLORIDE loperamide hydrochloride CAPSULE;ORAL 021855-001 Aug 4, 2005 OTC Yes No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Bionpharma Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0984957 CR 2012 00035 Denmark   Start Trial PRODUCT NAME: ET KOMBINATIONSPRODUKT AF NAPROXEN OG ESOMEPRAZOL MAGNESIUM TRIHYDRAT; NAT. REG. NO/DATE: 49583 20120327; FIRST REG. NO/DATE: GB PL 17901/0263-001 20101105
0984957 PA2011005 Lithuania   Start Trial PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
0637297 SPC/GB01/041 United Kingdom   Start Trial SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB01/041 GRANTED TO EISAI R + D MANAGEMENT., LTD. IN RESPECT OF THE PRODUCT BEXAROTENE (4-(1-(3, 5, 5, 8, 8-PENTAMETHYL-5, 6, 7, 8-TETRAHYDRO-2-NAPHTHALENYL)VINYL)BENZOIC ACID), WHICH WAS ADVERTISED AS COMING INTO FORCE IN JOURNAL NO 6469 DATED 15/05/2013 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, IT WILL EXPIRE ON 01/04/2016.
0152897 SPC/GB01/012 United Kingdom   Start Trial PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115
0113964 97C0037 Belgium   Start Trial PRODUCT NAME: OESTROGENES EQUINS CONJUGUES; ACETATE DE MEDROXYPROGESTERONE; NAT. REGISTRATION NO/DATE: NL 19569 19950301; FIRST REGISTRATION: CH - 52647 01 010 19940826
1411900 1190013-1 Sweden   Start Trial PRODUCT NAME: NAPROXEN OCH ESOMEPRAZOL; NAT. REG. NO/DATE: MTNR 43248 20101203; FIRST REG.: GB PL 17901/0263 20101105
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Moodys
Mallinckrodt
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.